Compare BW & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | AGIO |
|---|---|---|
| Founded | 1867 | 2007 |
| Country | United States | United States |
| Employees | 1650 | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 2.0B |
| IPO Year | 2015 | 2013 |
| Metric | BW | AGIO |
|---|---|---|
| Price | $7.92 | $33.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $8.00 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 4.9M | 777.0K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.46 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,062,388,000.00 | $43,011,000.00 |
| Revenue This Year | $41.58 | $76.75 |
| Revenue Next Year | $66.70 | $170.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.64 | $22.24 |
| 52 Week High | $22.03 | $46.00 |
| Indicator | BW | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 48.19 |
| Support Level | $6.75 | $32.54 |
| Resistance Level | $11.34 | $36.04 |
| Average True Range (ATR) | 0.47 | 1.28 |
| MACD | 0.08 | 0.10 |
| Stochastic Oscillator | 23.51 | 42.77 |
Babcock & Wilcox Enterprises Inc is an energy technologies provider offering energy and emissions control solutions to a broad range of industrial, electrical utility, municipal, and other customers. It offers technologies that utilize coal, natural gas, hydrogen, waste, and biomass to produce energy, environmental solutions, and carbon capture systems. The company's product portfolio comprises steam generation systems, environmental solutions, combustion and fuel systems, and related equipment and services. Additionally, it offers specialized technologies (BrightLoop) in industrial energy production, including hydrogen and syngas. Geographically, the company generates maximum revenue from the United States, and the rest from Canada, the UK, Indonesia, the Philippines, and other markets.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.